Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235108 | 0.85 | ALDH1A1 (0.38) | NPBWR1ALDH1A1KMT2AGRM2ELANE | |
| SCHEMBL11620916 | 0.73 | RAD51 (0.36) | KMT2AMEN1 | |
| SCHEMBL2236268 | 0.69 | MGLL (0.45) | ALDH1A1KMT2AMEN1HPGDHTT | |
| SCHEMBL11620524 | 0.69 | GSK3A (0.38) | GSK3AGSK3BMGLL | |
| SCHEMBL8718821 | 0.66 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1HPGDHTT | |
| SCHEMBL2855351 | 0.66 | ALOX5 (0.40) | GRM2GAAALOX5 | |
| SCHEMBL9553659 | 0.65 | GRM2 (0.36) | ALDH1A1KMT2AMEN1HTTGRM2 | |
| SCHEMBL9733457 | 0.62 | ELANE (0.43) | ALDH1A1KMT2AMEN1ELANEMGLL | |
| SCHEMBL10579386 | 0.62 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1HPGDHTT | |
| SCHEMBL24794874 | 0.60 | GRM2 (0.56) | KMT2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299264-B2 | Method for producing oxadiazolinone compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2357167-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | AHR, CYP1B1, AR | NPBWR1 3815/4885ALDH1A1 50/4885KMT2A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.